Oncopeptides AB (publ) (ONCO) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the Oncopeptides webcast for the first quarter of 2026. Please note the disclaimer regarding forward-looking statements. Today's presentation is led by myself, Sofia Hegis, and our CFO, Henrik Bergentoft. We delivered net sales of 25.4 million SEC in Q1 2026, a 91% increase compared to Q1 2025. Following the rights issue we announced in conjunction with our last quarterly update, the company held a cash position of 205.2 million SEK by the end of Q1. We remain on track to reach positive cash flow by 2027. During the quarter, we announced and completed a rights issue of approximately 200 million SEK. I would like to take this opportunity to thank all our shareholders, new and old, that choose to participate in the rights issue. I would also like to thank HealthCap, our main owner, for their continued support and trust in oncopeptides. We secured fast track designation for our window of opportunity clinical study in glioblastoma, which emphasizes the high unmet need for this very difficult to treat tumor. Additionally, we continued to underscore PEPAXTI's position in the treatment landscape through real-world data. During Q1, data was published in the European Journal of Hematology, which reinforces PEPAXTI's role in today's treatment landscape. Finally, we initiated the MARINA study to strengthen real-world evidence for PEPAXTI in Germany in partnership with IOMEDICO. Well worth mentioning in the events after the period is the announcement we made on Monday that we are intending to submit a type 2 variation to expand PEPAXTI's label into the third line, in addition to our current label in fourth line. We went over the announcement in detail on Monday and I will give a short recap later during this call. Now over to Henrik for a summary of the financials. Th...